These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
460 related articles for article (PubMed ID: 17853019)
1. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. May M; Siegsmund M; Hammermann F; Loy V; Gunia S Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019 [TBL] [Abstract][Full Text] [Related]
2. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67. Taftachi R; Ayhan A; Ekici S; Ergen A; Ozen H BJU Int; 2005 Mar; 95(4):650-4. PubMed ID: 15705097 [TBL] [Abstract][Full Text] [Related]
3. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Khatami A; Hugosson J; Wang W; Damber JE Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633 [TBL] [Abstract][Full Text] [Related]
4. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308 [TBL] [Abstract][Full Text] [Related]
11. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Tenta R; Koutsilieris M In Vivo; 2005; 19(5):911-20. PubMed ID: 16097446 [TBL] [Abstract][Full Text] [Related]
12. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095 [TBL] [Abstract][Full Text] [Related]
13. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. Vis AN; Noordzij MA; Fitoz K; Wildhagen MF; Schröder FH; van der Kwast TH J Urol; 2000 Dec; 164(6):2156-61. PubMed ID: 11061947 [TBL] [Abstract][Full Text] [Related]
15. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma. Hattab EM; Koch MO; Eble JN; Lin H; Cheng L J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733 [TBL] [Abstract][Full Text] [Related]
16. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy. Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127 [TBL] [Abstract][Full Text] [Related]
19. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients. May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719 [TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]